Fig. 5

EBNA2 type 1 and 2 occupancy at human disease risk loci. Statistical enrichment of the overlap between type 1 and type 2 EBNA2 ChIP-seq peaks with human disease risk genetic variants. A Top: Enrichment of full EBNA2 ChIP-seq peak sets at disease risk loci for diseases previously established for type 1 EBNA2 (multiple sclerosis (MS) and systemic lupus erythematosus (SLE)). Bottom: Enrichment of type-specific and shared EBNA2 peak sets. Datasets with significant overlap (as calculated by RELI) are marked with asterisks (P < 0.05). B Enrichment of type-specific EBNA2 ChIP-seq peak sets at all disease risk loci. Each dot represents RELI results (normalized -log corrected p-value) for EBNA2 enrichment for a given disease. Results were normalized to the max negative log p-value for each EBNA2 dataset to facilitate comparisons. The black line indicates equivalently significant enrichment for type 1 and type 2 EBNA2. Previously established “EBNA2 disorders” (dark blue dots) and other diseases discussed in the text are labeled. Disease abbreviations: CD Celiac Disease, IBD Inflammatory Bowel Disease, JIA Juvenile Idiopathic Arthritis, MS Multiple Sclerosis, PBC Primary Biliary Cholangitis, RA Rheumatoid Arthritis, SLE Systemic Lupus Erythematosus, T1D Type 1 Diabetes, UC Ulcerative Colitis